Vermillion Aspira Collaborating With Baylor Genetics on Ovarian Cancer Early Detection Test Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration. Aspira Eyes $11M in Private Equity Financing Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share. Aspira Labs to Evaluate GenomeSmart Genetic Test Recommendation Platform The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests. Vermillion Q4 Revenues Up 123 Percent The company posted an 11 percent year-over-year decline in OVA1 sales but more than doubled its average revenue per test, to $301 from $143 in Q4 2015. Vermillion, Quest Extend, Amend Ovarian Cancer Test Deal The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal. Mar 7, 2017 Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1 Mar 2, 2017 Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1 Feb 14, 2017 Vermillion Aims to Raise $10.7M Nov 10, 2016 Vermillion Q3 Revenues Up 89 Percent Sep 29, 2016 Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1 Aug 19, 2016 Vermillion Hoping New Service Business Will Boost Revenue Growth Premium Aug 10, 2016 Vermillion Q2 Revenues Up 33 Percent, OVA1 Sales Down May 16, 2016 Vermillion Q1 Revenues Down 47 Percent Apr 28, 2016 Clinical Utility Study Finds Vermillion's OVA1 Useful in Driving High-Risk Patients to Specialists Apr 18, 2016 Vermillion Receives First $2M of $4M Loan From State of Connecticut Mar 24, 2016 Vermillion Posts $361K in Q4 Revenues, Large Drop in OVA1 Sales Volume Mar 21, 2016 Vermillion Receives FDA 510(k) Clearance for Overa Feb 11, 2016 Vermillion Launching Pelvic Mass Registry With $7.5M From CPRIT Jan 22, 2016 Consortium Publishes Study on Ultrasound Approach to Evaluate Adnexal Masses Premium Dec 1, 2015 Vermillion Wins Medi-Cal Coverage for OVA1 Nov 20, 2015 Vermillion's Kaiser Collaboration Could Hold Keys to Broadening OVA1 Uptake Premium Nov 12, 2015 Vermillion Q3 Revenues Up 2 Percent Oct 30, 2015 With CE Mark, Vermillion Moving Toward Commercialization of Overa Test Premium Oct 26, 2015 Vermillion Receives CE Mark for Overa Aug 19, 2015 CareFirst BlueCross/Blue Shield to Cover Vermillion's OVA1 Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.